NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Approximately 92% of Sionna Therapeutics' (SION) market value was wiped out in one session following the Company's disclosure that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction. Shareholders who lost money on SION are encouraged to submit their losses for review now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The trading reaction was not attributable to an apparent liquidity shortfall. Sionna reported approximately $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, and a Q2 2026 net loss of $29.9 million, with runway stated into 2028. The repricing followed the disclosure of the Phase 2a clinical results: a placebo-adjusted sweat chloride change of -1.0 mmol/L, with a p-value of 0.7, when SION-719 was added to standard of care.
The Company stated it would not advance SION-719 as an add-on therapy. Shares had traded in the mid-$40s in the months preceding the readout. Levi & Korsinsky is investigating whether SION investors have legal claims in connection with the events surrounding that decline.
If you purchased Sionna Therapeutics shares and suffered a loss, start your no-cost claim evaluation here. You may also contact Joseph E. Levi, Esq. at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the SION Investigation
Q: How much did SION stock drop? A: Shares fell approximately 90%, from the mid-$40s to roughly $4 per share, after the Company disclosed that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction and that SION-719 would not advance as an add-on therapy. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Who is eligible to participate in the SION investigation? A: Investors who purchased SION stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: When did Sionna Therapeutics allegedly mislead investors? A: The investigation concerns statements made before the August 10, 2026 disclosure of the SION-719 Phase 2a results. The investigation is examining whether Sionna made materially misleading statements or omissions concerning SION-719 and its prospects that caused investors to purchase Sionna securities at allegedly inflated prices.
Q: What do SION investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my SION shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought SION and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
